FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Reverts Lab Test Reg. After Court Ruling

[ Price : $8.95]

FDA publishes a final rule rolling back a 2024 regulation that expanded the agencys authority over laboratory-developed tests.

FDA OKs Expanded Labeling for Asthma Drug

[ Price : $8.95]

FDA approves an AstraZeneca supplemental NDA for Airsupra (albuterol/budesonide) to expand the drugs labeling to reflect a 46% red...

Regeneron Plans Garetosmab FDA Submission

[ Price : $8.95]

Regeneron says it will submit an application to FDA by the end of 2025 seeking approval for its garetosmab to treat adults with fi...

Leverage FDA Alternative Tools Flexibility: Attorneys

[ Price : $8.95]

Three Sidley attorneys suggest ways drug companies can take advantage of the flexibility in FDAs guidance on using alternative too...

Alert on Abbotts TactiFlex Ablation Catheter

[ Price : $8.95]

FDA issues an alert after becoming aware that Abbott issued a letter to customers recommending updated instructions when removing ...

6 Observations in Fagron Outsourcing Inspection

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at Wichita, KS-based Fagron Compounding Services.

FDA Approves 2 Biocon Denosumab Biosimilars

[ Price : $8.95]

FDA approves Biocon Biologics biosimilars for Amgens Prolia and Xgeva.

Safety Labeling Changes Guidance

[ Price : $8.95]

FDA issues a draft guidance revising and updating a 2013 guidance on safety labeling changes when new safety information becomes a...

Committee Advances Pediatric Voucher Reauthorization

[ Price : $8.95]

The House Energy and Commerce Committee unanimously approves legislation to reauthorize FDAs Rare Pediatric Disease Priority Revie...

sGERD Drug Development Guidance

[ Price : $8.95]

FDA publishes a guidance to help sponsors with clinical trials for drugs to treat symptomatic nonerosive gastroesophageal reflux d...